Quantcast

Latest Adalimumab Stories

2014-10-01 16:27:17

Featured Presentations Highlight Data From Approved and Investigational Agents Across Amgen's Dermatology Portfolio THOUSAND OAKS, Calif., Oct. 1, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present several studies related to brodalumab, Enbrel(®) (etanercept) and ABP 501 (adalimumab biosimilar) at the 23(rd) Congress of the European Academy of Dermatology and Venereology (EADV) in Amsterdam, Oct. 8-12, 2014. These data reinforce Amgen's continued commitment to...

2014-09-25 08:27:02

-- HUMIRA is now indicated to treat pediatric patients 6 years of age and older with moderately to severely active Crohn's disease who have had an inadequate response to corticosteroids or immunomodulators such as azathioprine, 6-mercaptopurine, or methotrexate NORTH CHICAGO, Ill., Sept. 25, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) has approved HUMIRA(®) (adalimumab) for reducing signs and symptoms, and achieving and...

2014-09-17 12:25:34

Improved Efficacy and Lower List Price than the Anti-TNFs Will Be the Key Drivers for Prescribing of Emerging Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 17, 2014 /PRNewswire/ -- Decision Resources Group finds that among Crohn's disease/ulcerative colitis (CD/UC) patients eligible for biologic therapy, only a proportion of patients currently receive a biologic. Surveyed gastroenterologists cite patients' discomfort with biological therapy as the...

2014-09-16 12:30:41

Rheumatologists Report that the Vast Majority of RA Patients Who are Candidates for Biologic Treatment Receive a Biologic, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 16, 2014 /PRNewswire/ -- Decision Resources Group finds that the percentage of rheumatoid arthritis (RA) patients treated with a biologic agent by rheumatologists has remained relatively constant since 2012 in the major European markets (France, Germany, Italy, Spain and the United Kingdom)....

2014-09-16 12:30:11

The Imminent Entry of Biosimilars Will Constrain Sales of Branded Biologics and Premium-Priced Emerging Agents, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 16, 2014 /PRNewswire/ -- Decision Resources Group finds that the rheumatoid arthritis (RA) disease-modifying antirheumatic drug market will increase from $14 billion in 2013 to over $18.2 billion in 2023 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. TNF-alpha inhibitors...

2014-09-11 04:21:10

- Currently no approved treatment options available for patients living with HS, a skin disease which impacts approximately 1 percent of the adult population worldwide1,2 COPENHAGEN, Denmark, Sept. 11, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced results from a Phase 3 pivotal study demonstrating that HUMIRA(®) (adalimumab) is effective in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and...

2014-09-08 12:24:27

TNF-Alpha Inhibitors--Including Sales Leader Humira--Accounted for Over 90 Percent of the Psoriatic Arthritis Market, According to Findings from Decision Resources Group BURLINGTON, Mass., Sept. 8, 2014 /PRNewswire/ -- Decision Resources Group finds that the market for psoriatic arthritis (PsA) therapies will grow nearly 66 percent, increasing to $3.7 billion in 2023, owing to the continued uptake of premium-price biologics and novel therapies that are expected to launch during the 2013 to...

2014-08-14 16:27:44

Company To Pursue Next Stage of Development REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira(®) in healthy subjects. The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined,...

2014-08-05 08:34:27

Supports progression of this first-in-class anti-TLR4 monoclonal antibody into clinical proof of concept study as a potential personalized medicine for rheumatoid arthritis GENEVA, August 5, 2014 /PRNewswire/ -- Novimmune SA, a company focused on the discovery and development of antibody-based drugs to benefit patients with inflammatory, auto-immune disorders, and cancer announces today the completion of a comprehensive Phase I clinical trial investigating the pharmacokinetics,...

2014-07-17 08:29:29

Nearly half a million dollars given to early-career physicians to study psoriatic disease PORTLAND, Ore., July 17, 2014 /PRNewswire-USNewswire/ -- Twelve residents and medical students each received a one-year, $50,000 National Psoriasis Foundation fellowship to study psoriasis. The fellowships aim to increase the number of scientists studying and treating psoriatic disease by encouraging promising doctors to dedicate their careers to the study of psoriasis and psoriatic arthritis as...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related